Show Notes
Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy —as one of the only women of color leading a major pharmaceutical company.
This episode was recorded on April 23, 2025. Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Talks at GS
OpenEvidence is working to rapidly advance clinical decision-making, emerging as a global leader in delivering gold-standard medical knowledge to physicians at the point of care. Daniel Nadler, co-founder and CEO of OpenEvidence, joins Meena Flynn, chair of Global Private Wealth Management and co-head of One Goldman Sachs, to discuss OpenEvidence's founding story, how the platform acts as a “brain extender” for doctors, and the future of matching patients with life-saving clinical trials.
U.S. Soccer has entered a transformative era, driving the growth of the sport across the nation as it capitalizes on hosting the 2026 World Cup and other global sporting tournaments to come. JT Batson, CEO and secretary general of U.S. Soccer, joins Dave Dase, head of Goldman Sachs' global sports business, to discuss the legacy of the World Cup, U.S. Soccer’s strategic plans through the 2028 Los Angeles Olympics and the 2031 Women’s World Cup, and how an invigorated grassroots culture could make the U.S. "one of the world's great soccer countries."
The luxury real estate brokerage SERHANT. generates over $1 billion in transactions every month. On Talks at GS, Ryan Serhant, founder and CEO of SERHANT., joins Tucker York, chair of Goldman Sachs global Wealth Management, to discuss his transition from the theatre to real estate during the 2008 financial crisis, his video-led sales strategies, and how calculated risks have led to the company’s success.
WellWithAll is a purpose-led health and wellness company built on an inclusive capitalism model that reinvests 20% of its profits into health equity initiatives to help close the wellness gap across generations. Demond Martin, co-founder and CEO of WellWithAll, joins Kim Posnett, global co-head of Investment Banking at Goldman Sachs, to discuss his transition from a 21-year career on Wall Street to becoming a founder, and how his philosophy of building deep, value-aligned relationships—as described in his book Friends of the Good—has shaped his approach to mentorship and leading a mission-driven business.
The NobleReach Foundation taps into leaders across sectors – technology, science, government, academia – who have a penchant for national service and a desire to bridge the gap between a flourishing private sector career and large-scale public problem-solving. Arun Gupta, NobleReach’s CEO, joins John Mallory, co-head of Wealth Management at Goldman Sachs, to describe careers that are rich in "hidden capital"—trust, learning, and mission—and that align personal ambition with civic responsibility amid rapid AI disruption and geopolitical change.